title: Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.
abstract: Upregulation of group IIA phospholipase A(2) (sPLA(2)-IIA) correlates with prostate tumor progression suggesting prooncogenic properties of this protein. Here, we report data on expression of three different sPLA(2) isozymes (groups IIA, V, and X) in normal (PrEC) and malignant (DU-145, PC-3, and LNCaP) human prostate cell lines. All studied cell lines constitutively expressed sPLA(2)-X, whereas sPLA(2)-V transcripts were identified only in malignant cells. In contrast, no expression of sPLA(2)-IIA was found in PrEC and DU-145 cells, but it was constitutively expressed by IFN-gamma in LNCaP and PC-3 cells. Expression of sPLA(2)-IIA is upregulated in PC-3 and in PrEC cell in a signal transducer and activator of transcription-1-dependent manner, but not in LNCaP cell. Additional signaling pathways regulating sPLA(2)-IIA expression include cAMP/protein kinase A, p38 mitogen-activated protein kinase, protein kinase C, Rho-kinase, and mitogen-activated/extracellular response protein kinase / extracellular signal-regulated kinase. No deletions were revealed in the sPLA(2)-IIA gene from DU-145 cells lacking the expression of sPLA(2)-IIA. Reexpression of sPLA(2)-IIA was induced by 5-aza-2'-deoxycytidine demonstrating that DNA methylation is implicated in the regulation of sPLA(2)-II. Together, these data suggest that sPLA(2)-IIA and sPLA(2)-V, but not sPLA(2)-X, are differentially expressed in normal and malignant prostate cells under the control of proinflammatory cytokines; epigenetic mechanisms appear involved in the regulation of sPLA(2)-IIA expression, at least in DU-145 cells.
authors.affiliation: Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus, Institut für Klinische Chemie und Laboratoriumsmedizin, Dresden, Germany. menschik@rcs.urz.tu-dresden.de
authors.forename: Mario
authors.initials: M
authors.lastname: Menschikowski
authors.forename: Albert
authors.initials: A
authors.lastname: Hagelgans
authors.forename: Eugene
authors.initials: E
authors.lastname: Gussakovsky
authors.forename: Heike
authors.initials: H
authors.lastname: Kostka
authors.forename: Elena L
authors.initials: EL
authors.lastname: Paley
authors.forename: Gabriele
authors.initials: G
authors.lastname: Siegert
mesh_terms: D045744:Cell Line, Tumor; D016207:Cytokines / Q000378:metabolism* / Q000494:pharmacology; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D044127:Epigenesis, Genetic; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D054501:Group II Phospholipases A2 / Q000235:genetics*; D054505:Group V Phospholipases A2 / Q000235:genetics*; D054509:Group X Phospholipases A2 / Q000235:genetics*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007527:Isoenzymes / Q000235:genetics; D008297:Male; D011467:Prostate / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology; D015398:Signal Transduction; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D016207:Cytokines; D007527:Isoenzymes; D014157:Transcription Factors; D007371:Interferon-gamma; D015254:DNA Modification Methylases; D054501:Group II Phospholipases A2; D054505:Group V Phospholipases A2; D054509:Group X Phospholipases A2